Review of Strategic Alternatives

Review of Strategic Alternatives

DUBLIN, April 30, 2012 (GLOBE NEWSWIRE) -- Further to media speculation, the
Board of Warner Chilcott plc (Nasdaq:WCRX) confirmed today that it is
conducting a process to explore a broad range of strategic alternatives to
enhance shareholder value, which include preliminary discussions with
potential offerors.

These discussions are at a preliminary stage and may or may not lead to an
offer for the Company.

The Company does not intend to disclose further developments regarding the
process unless and until its Board has approved a specific course of action,
or it otherwise deems further disclosure is appropriate or required.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently
focused on the women's healthcare, gastroenterology, dermatology and urology
segments of the branded pharmaceuticals market, primarily in North America. We
are a fully integrated Company with internal resources dedicated to the
development, manufacturing and promotion of our products. WCRX-G

A person interested in 1% or more of any relevant securities in the Company
may from the date of this announcement have disclosure obligations under Rule
8.3 of the Irish Takeover Rules.

The directors of the Company accept responsibility for the information
contained in this announcement. To the best of the knowledge and belief of the
directors (who have taken all reasonable care to ensure that such is the case)
the information contained in this announcement is in accordance with the facts
and does not omit anything likely to affect the import of such information.

Goldman Sachs International, which is authorised and regulated in the United
Kingdom by the Financial Services Authority, is acting exclusively for the
Company and for no-one else in connection with the matters set out in this
announcement and will not be responsible to any person other than the Company
for providing the protections afforded to clients of Goldman Sachs
International, nor for providing advice in relation to the matters set out in
this announcement.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE
OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION
WHERE THIS WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH
JURISDICTION.

CONTACT: Enquiries
        
         Warner Chilcott plc
        
         Emily Hill
         Investor Relations
         (973) 907-7084
         Emily.Hill@wcrx.com

Warner Chilcott Logo
 
Press spacebar to pause and continue. Press esc to stop.